Evidence map›Paper›PMID 39328842›Full record

ArticleJournal of pharmaceutical policy and practice2024

Trends in medicine utilisation in public and private healthcare facilities before and during COVID-19: a nationwide analysis of medicine procurement and sales data, 2018-2022.

Norazida Ab Rahman, Ee Vien Low, Audrey Huili Lim, Azzy Iyzati Ahmad Shanizza, See Wan Ho, Mardhiyah Kamal, Abdul Haniff Mohamad Yahaya, Sheamini Sivasampu

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Norazida Ab RahmanInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0001-6439-2005
Ee Vien LowInstitute for Health Systems Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0001-8596-1318
Audrey Huili LimInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0001-6721-1505
Azzy Iyzati Ahmad ShanizzaPharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.ORCID https://orcid.org/0000-0003-0368-0227
See Wan HoPharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.
Mardhiyah KamalPharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.
Abdul Haniff Mohamad YahayaPharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia.ORCID https://orcid.org/0000-0002-4591-7053
Sheamini SivasampuInstitute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0003-2314-6048

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There was a fluctuation in medication demand and supply during COVID-19 pandemic. This study aimed to assess the trend of drug utilisation in Malaysia in 2018-2022 and evaluate the impact of COVID-19 on drug utilisation rates. Methods: We conducted a repeated cross-sectional study of pharmaceutical sales data from public and private sectors in Malaysia from 2018 to 2022. Drug utilisation rates for the period after the onset of COVID-19 (2020-2022) was compared with the earlier period (2018-2019). Interrupted time-series regression analyses evaluated level and slope changes compared to pre-COVID-19 pandemic level for quarterly rates of drugs utilisation in public and private sectors. Results: There was an immediate reduction in the utilisation rates for all drugs after COVID-19 in public (-20.4%; Conclusion: A significant reduction in the overall drug utilisation rates was observed in the public and private sectors in Malaysia as an immediate impact of the COVID-19 pandemic in 2020. The impacts varied by therapeutic class and health sector. This finding provides an understanding of the changing patterns of drug utilisation that were affected by disease outbreaks for future planning of pandemic preparedness.

Indexed as

COVID-19Drug utilisationpharmacoepidemiology

Identifiers

PMID39328842
PMCPMC11425687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.